[HTML][HTML] Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®
Purpose The chimeric monoclonal antibody (mAb) chDAB4 (APOMAB®) targets the Lupus
associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in tumors but …
associated (La)/Sjögren Syndrome-B (SSB) antigen, which is over-expressed in tumors but …
[HTML][HTML] Positron emission tomographic imaging of tumor cell death using Zirconium-89-labeled APOMAB® following cisplatin chemotherapy in lung and ovarian …
Purpose Early detection of tumor treatment responses represents an unmet clinical need
with no approved noninvasive methods. DAB4, or its chimeric derivative, chDAB4 …
with no approved noninvasive methods. DAB4, or its chimeric derivative, chDAB4 …
[HTML][HTML] Development and Preclinical Evaluation of [68Ga]BMSH as a New Potent Positron Emission Tomography Tracer for Imaging Programmed Death-Ligand 1 …
Y Huang, C Li, Z Li, Q Wang, S Huang, Q Liu, Y Liang - Pharmaceuticals, 2023 - mdpi.com
Immunotherapy targeting the programmed death-ligand 1 (PD-L1)/programmed cell death
protein 1 (PD-1) pathway has shown remarkable efficacy against various cancers, but the …
protein 1 (PD-1) pathway has shown remarkable efficacy against various cancers, but the …
[HTML][HTML] APOMAB®, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy
Background Antineoplastic therapy may impair the survival of malignant cells to produce cell
death. Consequently, direct measurement of tumor cell death in vivo is a highly desirable …
death. Consequently, direct measurement of tumor cell death in vivo is a highly desirable …
Apoptosis imaging probe predicts early chemotherapy response in preclinical models: a comparative study with 18F-FDG PET
S Song, C Xiong, W Lu, G Ku, G Huang… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Previously, we reported a small-molecular-weight peptide, single amino acid chelae
(99mTc)-conjugated phosphatidylserine-binding peptide (SAAC (99mTc)-PSBP-6), with high …
(99mTc)-conjugated phosphatidylserine-binding peptide (SAAC (99mTc)-PSBP-6), with high …
[HTML][HTML] Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues
MP Kelly, S Makonnen, C Hickey… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1)
blocking antibodies including cemiplimab have generated profound clinical activity across …
blocking antibodies including cemiplimab have generated profound clinical activity across …
Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody
APOMAB (chDAB4) is a dead tumour cell-targeting antibody which has been used
preclinically as a diagnostic agent and therapeutically as a radioimmunotherapy and …
preclinically as a diagnostic agent and therapeutically as a radioimmunotherapy and …
Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using a zirconium-89 labeled therapeutic antibody, avelumab
EM Jagoda, O Vasalatiy, F Basuli… - Molecular …, 2019 - journals.sagepub.com
Objective: The goal is to evaluate avelumab, an anti-PD-L1 monoclonal immunoglobulin G
antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse …
antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse …
Synthesis and preclinical evaluation of a 68Ga-labeled adnectin, 68Ga-BMS-986192, as a PET agent for imaging PD-L1 expression
S Robu, A Richter, D Gosmann, C Seidl… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Blocking the interaction of the immune checkpoint molecule programmed cell death protein-
1 and its ligand, PD-L1, using specific antibodies has been a major breakthrough for …
1 and its ligand, PD-L1, using specific antibodies has been a major breakthrough for …
[HTML][HTML] Preclinical antibody-PET imaging of PD-L1
EL Brown, RA DeWeerd, A Zidel… - Frontiers in Nuclear …, 2022 - frontiersin.org
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade, including antibody
therapeutics, has transformed cancer treatment. However, a major challenge in the field …
therapeutics, has transformed cancer treatment. However, a major challenge in the field …